Patient characteristics
| . | Patients with CD34+ cell samples (n = 100) . | Patients with BMMNC samples only (n = 114) . | ||||
|---|---|---|---|---|---|---|
| First (EMK) subgroup . | Second (IMP) subgroup . | P . | First (EMK) subgroup . | Second (IMP) subgroup . | P . | |
| Number of cases | 61 | 39 | — | 71 | 43 | — |
| Age (y), median (range) | 69 (32–87) | 62 (30–83) | .01 | 67 (30–83) | 67 (39–91) | .46 |
| Sex (male/female) | 38/23 | 27/12 | .52 | 42/27 | 29/18 | 1 |
| Diagnosis, n (%) | ||||||
| MDS | 37 (61) | 22 (56) | — | 57 (80) | 36 (84) | — |
| MDS-SLD | 4 (6.6) | 1 (2.6) | .65 | 5 (7.0) | 1 (2.3) | .41 |
| MDS-RS-SLD | 13 (21) | 1 (2.6) | .008 | 19 (27) | 1 (2.3) | <.001 |
| MDS-MLD | 5 (8.2) | 4 (10) | .73 | 13 (18) | 17 (40) | .02 |
| MDS-RS-MLD | 5 (8.2) | 2 (5.1) | .70 | 9 (13) | 1 (2.3) | .09 |
| MDS with isolated del(5q) | 2 (3.3) | 0 (0) | .52 | 1 (1.4) | 1 (2.3) | 1 |
| MDS-EB-1 | 4 (6.6) | 5 (13) | .31 | 7 (9.9) | 6 (14) | .55 |
| MDS-EB-2 | 4 (6.6) | 9 (23) | .03 | 3 (4.2) | 9 (22) | .009 |
| MDS/MPN | 24 (39) | 6 (15) | — | 13 (18) | 1 (2.3) | — |
| CMML-1 | 19 (31) | 5 (13) | .05 | 8 (11) | 0 (0) | .02 |
| CMML-2 | 1 (1.6) | 0 (0) | 1 | 0 (0) | 0 (0) | 1 |
| MDS/MPN-RS-T | 4 (6.6) | 0 (0) | .15 | 3 (4.2) | 1 (2.3) | 1 |
| MDS/MPN-U | 0 (0) | 1 (2.6) | .39 | 2 (2.8) | 0 (0) | .53 |
| AML-MDS | 0 (0) | 11 (28) | <.001 | 1 (1.4) | 6 (14) | .01 |
| Hemoglobin (g/dL), median (range) | 10.4 (7.0-14.7) | 10.2 (7.0-14.4) | .92 | 9.8 (6.3-15.5) | 9.7 (6.8-13.9) | .43 |
| ANC (×109/L), median (range) | 3.0 (0.35-13) | 1.7 (0.40-32) | .06 | 2.1 (0.20-22) | 1.3 (0.20-11) | .002 |
| Platelet count (×109/L), median (range) | 173 (17.5-895) | 76.0 (15.0-697) | <.001 | 175 (16.0-849) | 102 (12.5-939) | .03 |
| Myeloid/erythroid ratio, median (range) | 2.0 (0.50–10) | 2.0 (0.13–10) | .86 | 2.0 (0.25-10) | 1.5 (0.20-10) | .71 |
| Bone marrow blasts (%), median (range) | 2 (0–15) | 11 (1–90) | <.001 | 2 (0-86) | 4 (0-63) | .003 |
| Bone marrow ring sideroblasts (%), median (range) | 9 (0–94) | 5 (0–78) | .20 | 13 (0–94) | 0.3 (0–81) | .08 |
| IPSS-R in the patients with MDS, n (%) | ||||||
| Very low | 0 (0) | 0 (0) | 1 | 0 (0) | 0 (0) | 1 |
| Low | 15 (25) | 3 (7.7) | .04 | 26 (37) | 10 (23) | .15 |
| Intermediate | 12 (20) | 7 (18) | 1 | 17 (24) | 8 (19) | .64 |
| High | 7 (11) | 5 (13) | 1 | 9 (13) | 10 (23) | .19 |
| Very high | 3 (4.9) | 7 (18) | .04 | 3 (4.2) | 6 (14) | .08 |
| Missing | 0 (0) | 0 (0) | 1 | 2 (2.8) | 2 (4.7) | .63 |
| Treatment during the follow-up period,*n (%) | ||||||
| Allogeneic stem cell transplantation | 3 (4.9) | 7 (18) | .04 | 4 (5.6) | 4 (9.3) | .47 |
| Cytotoxic chemotherapy | 0 (0) | 7 (18) | <.001 | 2 (2.8) | 6 (14) | .05 |
| Azacitidine | 3 (4.9) | 2 (11) | 1 | 3 (4.2) | 4 (9.3) | .42 |
| Response | 1 (33) | 0 (0) | 1 | 0 (0) | 1 (25) | 1 |
| Only supportive care | 56 (92) | 26 (67) | .003 | 63 (89) | 31 (72) | .04 |
| . | Patients with CD34+ cell samples (n = 100) . | Patients with BMMNC samples only (n = 114) . | ||||
|---|---|---|---|---|---|---|
| First (EMK) subgroup . | Second (IMP) subgroup . | P . | First (EMK) subgroup . | Second (IMP) subgroup . | P . | |
| Number of cases | 61 | 39 | — | 71 | 43 | — |
| Age (y), median (range) | 69 (32–87) | 62 (30–83) | .01 | 67 (30–83) | 67 (39–91) | .46 |
| Sex (male/female) | 38/23 | 27/12 | .52 | 42/27 | 29/18 | 1 |
| Diagnosis, n (%) | ||||||
| MDS | 37 (61) | 22 (56) | — | 57 (80) | 36 (84) | — |
| MDS-SLD | 4 (6.6) | 1 (2.6) | .65 | 5 (7.0) | 1 (2.3) | .41 |
| MDS-RS-SLD | 13 (21) | 1 (2.6) | .008 | 19 (27) | 1 (2.3) | <.001 |
| MDS-MLD | 5 (8.2) | 4 (10) | .73 | 13 (18) | 17 (40) | .02 |
| MDS-RS-MLD | 5 (8.2) | 2 (5.1) | .70 | 9 (13) | 1 (2.3) | .09 |
| MDS with isolated del(5q) | 2 (3.3) | 0 (0) | .52 | 1 (1.4) | 1 (2.3) | 1 |
| MDS-EB-1 | 4 (6.6) | 5 (13) | .31 | 7 (9.9) | 6 (14) | .55 |
| MDS-EB-2 | 4 (6.6) | 9 (23) | .03 | 3 (4.2) | 9 (22) | .009 |
| MDS/MPN | 24 (39) | 6 (15) | — | 13 (18) | 1 (2.3) | — |
| CMML-1 | 19 (31) | 5 (13) | .05 | 8 (11) | 0 (0) | .02 |
| CMML-2 | 1 (1.6) | 0 (0) | 1 | 0 (0) | 0 (0) | 1 |
| MDS/MPN-RS-T | 4 (6.6) | 0 (0) | .15 | 3 (4.2) | 1 (2.3) | 1 |
| MDS/MPN-U | 0 (0) | 1 (2.6) | .39 | 2 (2.8) | 0 (0) | .53 |
| AML-MDS | 0 (0) | 11 (28) | <.001 | 1 (1.4) | 6 (14) | .01 |
| Hemoglobin (g/dL), median (range) | 10.4 (7.0-14.7) | 10.2 (7.0-14.4) | .92 | 9.8 (6.3-15.5) | 9.7 (6.8-13.9) | .43 |
| ANC (×109/L), median (range) | 3.0 (0.35-13) | 1.7 (0.40-32) | .06 | 2.1 (0.20-22) | 1.3 (0.20-11) | .002 |
| Platelet count (×109/L), median (range) | 173 (17.5-895) | 76.0 (15.0-697) | <.001 | 175 (16.0-849) | 102 (12.5-939) | .03 |
| Myeloid/erythroid ratio, median (range) | 2.0 (0.50–10) | 2.0 (0.13–10) | .86 | 2.0 (0.25-10) | 1.5 (0.20-10) | .71 |
| Bone marrow blasts (%), median (range) | 2 (0–15) | 11 (1–90) | <.001 | 2 (0-86) | 4 (0-63) | .003 |
| Bone marrow ring sideroblasts (%), median (range) | 9 (0–94) | 5 (0–78) | .20 | 13 (0–94) | 0.3 (0–81) | .08 |
| IPSS-R in the patients with MDS, n (%) | ||||||
| Very low | 0 (0) | 0 (0) | 1 | 0 (0) | 0 (0) | 1 |
| Low | 15 (25) | 3 (7.7) | .04 | 26 (37) | 10 (23) | .15 |
| Intermediate | 12 (20) | 7 (18) | 1 | 17 (24) | 8 (19) | .64 |
| High | 7 (11) | 5 (13) | 1 | 9 (13) | 10 (23) | .19 |
| Very high | 3 (4.9) | 7 (18) | .04 | 3 (4.2) | 6 (14) | .08 |
| Missing | 0 (0) | 0 (0) | 1 | 2 (2.8) | 2 (4.7) | .63 |
| Treatment during the follow-up period,*n (%) | ||||||
| Allogeneic stem cell transplantation | 3 (4.9) | 7 (18) | .04 | 4 (5.6) | 4 (9.3) | .47 |
| Cytotoxic chemotherapy | 0 (0) | 7 (18) | <.001 | 2 (2.8) | 6 (14) | .05 |
| Azacitidine | 3 (4.9) | 2 (11) | 1 | 3 (4.2) | 4 (9.3) | .42 |
| Response | 1 (33) | 0 (0) | 1 | 0 (0) | 1 (25) | 1 |
| Only supportive care | 56 (92) | 26 (67) | .003 | 63 (89) | 31 (72) | .04 |
AML-MDS, AML with myelodysplasia-related changes; ANC, absolute neutrophil count; CMML, chronic myelomonocytic leukemia; MDS-EB, MDS with excess of blasts; MDS-MLD, MDS with multilineage dysplasia; MDS/MPN, myelodysplastic/myeloproliferative neoplasm; MDS/MPN-RS-T, MDS/MPN with ring sideroblasts and thrombocytosis; MDS/MPN-U, MDS/MPN, unclassifiable; MDS-RS-SLD, MDS with ring sideroblasts with single-lineage dysplasia; MDS-SLD, MDS with single-lineage dysplasia; MDS-RS-MLD, MDS with ring sideroblasts with multilineage dysplasia.
Some patients received various treatments (eg, cytotoxic chemotherapy followed by allogeneic stem cell transplantation). This led to the sums of patients exceeding 100%.